tbuckley/cabot-search huggingface dataset:
Visualization Of Normal and Malignant Epigenetic Regulation In Hematopoiesis Utilizing Newly-Developed Histone Variant H3.3 Chipseq Analysis
Authors: Jun Odawara, Kohta Miyawaki, Junichiro Yuda, Masayasu Hayashi, Kazumitsu Maehara, Takahiro Shima, Yoshikane Kikushige, Yasuyuki Ohkawa, Koichi Akashi
Journal: Blood (2013)
Combined Loss of Tet1 and Tet2 Promotes B-Cell, but Not Myeloid Malignancies in Mice
Authors: Zhigang Zhao, Lin Li, Meelad Dawlaty, Feng Pan, Zhe Li, Yuan Zhou, Hui Shi, Shi Chen, Ophelia Weeks, Weiping Yuan, Hongyu Ni, Feng-Chun Yang, Rudolph Jaenisch, Peng Jin, Mingjiang Xu
Journal: Blood (2015)
Elemene augments 5-fluorouracil sensitivity in cyclooxygenase-2-expressing colon cancer cells through a mitochondria-mediated apoptotic pathway
Authors: Hong Ding, Gangduo Wang, Xiping Li, Jinshun Zhao, Daniel C. Flynn, Eddie Reed, Qingdi Q. Li
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

5756 

5-Fluorouracil (5-FU) is the most commonly used drug for the treatment of colorectal cancer, but its effect is affected by cyclooxygenase-2 ( COX-2 ) overexpression. Elemene is a novel plant antitumor agent; however, its effect in colon cancer is not understood. In this study, we demonstrated that elemene had a greater antitumor activity in Caco-2 and Colo-205 colon cancer cells, expressing endogenous COX-2 than in HCT-15 and HCT-116 colon cancer cells, lacking endogenous COX-2. Our further studies on the interactive effects of 5-Fu and elemene in these cells showed that the combination of elemene with 5-FU resulted in antagonistic effects in all of the four cell lines when treated with both drugs simultaneously. Interestingly enough, sequential exposure of the cells to elemene followed by 5-FU produced synergistic effects in Colo-205 and Caco-2 cells, but antagonistic effects in HCT-15 and HCT-116 cells. Apoptosis induction in Colo-205 and Caco-2 cells, but not in HCT-15 and HCT-116 cells, was also significantly increased after sequential treatment, as determined by TUNEL assay and Annexin-V/PI double staining analysis. Consistent with these results, we found that the sequential treatment with elemene and 5-FU also reduced the mitochondrial transmembrane potential (m), and increased the release of cytochrome c into the cytosol in Colo-205 and Caco-2 cells but not in HCT-15 and HCT-116 cells. Finally, we analyzed caspase activity by Western blotting, and our data revealed that the activation of caspase-3 and -9 was observed in Colo-205 and Caco-2 cells, but not in HCT-15 and HCT-116 cells, following sequential treatment with both agents. These findings suggest that elemene may enhance the effect of 5-Fu in colon cancer cells through a COX-2-dependent apoptotic pathway. Studies are in the works to investigate the mechanisms underlying the role of COX-2 in elemene effect on 5-FU cytotoxicity and apoptosis in human colon cancer cells. This study was supported by NIH/NCRR grant P20 RR16440.
Exome-Wide Association Study Identifies Low-Frequency Coding Variants in 2p23.2 and 7p11.2 Associated with Survival of Non–Small Cell Lung Cancer Patients
Authors: Meng Zhu, Liguo Geng, Wei Shen, Yuzhuo Wang, Jia Liu, Yang Cheng, Cheng Wang, Juncheng Dai, Guangfu Jin, Zhibin Hu, Hongxia Ma, Hongbing Shen
Journal: Journal of Thoracic Oncology (2017)
The Overexpression of Enhancer of Zeste Homologue 2 Is Associated with Tumor Proliferation and Aggressive Behavior in Adult T-Cell Leukemia/Lymphoma.
Authors: Daisuke Sasaki, Yoshitaka Imaizumi, Hiroo Hasegawa, Akemi Osaka, Kazuto Tsuruda, Kunihiro Tsukasaki, Masako Iwanaga, Yasushi Miyazaki, Katsunori Yanagihara, Victor Marquez, Shimeru Kamihira, Yasuaki Yamada
Journal: Blood (2009)
Myelodysplastic syndromes and bone loss in mice and men
Authors: H Weidner, M Rauner, F Trautmann, J Schmitt, E Balaian, A Mies, S Helas, U Baschant, C Khandanpour, M Bornhäuser, L C Hofbauer, U Platzbecker
Journal: Leukemia (2017)
Evaluation of 243 Patients with Myelodysplastic Syndrome (MDS) Referred for Hematopoietic Cell Transplant (HCT) Including Donor Availability and HCT Outcomes.
Authors: Teresa Field, Janelle Perkins, Mohamed A Kharfan-Dabaja, Hugo F. Fernandez, Lia Perez, J. Leonel Ochoa-Bayona, Jeffrey E Lancet, Rami S. Komrokji, Melissa Alsina, Ernesto Ayala, Alan F List, Claudio Anasetti
Journal: Blood (2009)
Efficacy and Safety of Early Administration of Mycophenolate Mofetil to Steroid-Resistant Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation: A Single Institution Study.
Authors: Masaki Mori, Kazuo Muroi, Tomohiro Matsuyama, Satoko Oka, Chizuru Yamamoto, Keiya Ozawa
Journal: Blood (2007)
Outcome of Relapse After Allogeneic Stem Cell Transplantation (SCT) In Patients with acute Myeloid Leukaemia (AML).
Authors: Raynier Devillier, Roberto Crocchiolo, Anne Etienne, Thomas Prebet, Aude Charbonnier, Sabine Furst, Jean El Cheikh, Evelyne D’Incan, Jerome Rey, Catherine Faucher, Didier Blaise, Norbert Vey
Journal: Blood (2010)
Treatment of Good Prognosis CD20+ Large-Cell Lymphomas in Patients Aged 65 to 80, with 3 Cycles of R-CHOP14 Followed by An Injection of 90Y Ibritumomab Tiuxetan
Authors: Peyrade Frederic, Lepeu Gérard, Mariano Provencio, Gastaud Lauris, Fontana Xavier, Broglia Jean-Marc, Carrier Patricia, Chamorey Emmanuel, Hebert Christophe, Antoine Thyss
Journal: Blood (2008)
Pharmacological rescue of diabetic skeletal stem cell niches
Authors: Ruth Tevlin, Eun Young Seo, Owen Marecic, Adrian McArdle, Xinming Tong, Bryan Zimdahl, Andrey Malkovskiy, Rahul Sinha, Gunsagar Gulati, Xiyan Li, Taylor Wearda, Rachel Morganti, Michael Lopez, Ryan C. Ransom, Christopher R. Duldulao, Melanie Rodrigues, Allison Nguyen, Michael Januszyk, Zeshaan Maan, Kevin Paik, Kshemendra-Senarath Yapa, Jayakumar Rajadas, Derrick C. Wan, Geoffrey C. Gurtner, Michael Snyder, Philip A. Beachy, Fan Yang, Stuart B. Goodman, Irving L. Weissman, Charles K. F. Chan, Michael T. Longaker
Journal: Science Translational Medicine (2017)

Diabetes mellitus (DM) is a metabolic disease frequently associated with impaired bone healing. Despite its increasing prevalence worldwide, the molecular etiology of DM-linked skeletal complications remains poorly defined. Using advanced stem cell characterization techniques, we analyzed intrinsic and extrinsic determinants of mouse skeletal stem cell (mSSC) function to identify specific mSSC niche-related abnormalities that could impair skeletal repair in diabetic (Db) mice. We discovered that high serum concentrations of tumor necrosis factor-α directly repressed the expression of Indian hedgehog (Ihh) in mSSCs and in their downstream skeletogenic progenitors in Db mice. When hedgehog signaling was inhibited during fracture repair, injury-induced mSSC expansion was suppressed, resulting in impaired healing. We reversed this deficiency by precise delivery of purified Ihh to the fracture site via a specially formulated, slow-release hydrogel. In the presence of exogenous Ihh, the injury-induced expansion and osteogenic potential of mSSCs were restored, culminating in the rescue of Db bone healing. Our results present a feasible strategy for precise treatment of molecular aberrations in stem and progenitor cell populations to correct skeletal manifestations of systemic disease.
The sFLT-1 to PlGF Ratio is Impaired in Patients with Thalassemia and Sickle Cell Disease.
Authors: Ioannis Papassotiriou, Alexandra Kouraklis-Symeonidis, Filia Apostolakou, Athanassios Akalestos, Vlassis Vlazakis, Vassilios Ladis, Antonios Kattamis
Journal: Blood (2009)
Results of Allogeneic Hematopoietic Cell Transplantation in Persons with Fanconi Anemia and Pretransplant Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia
Authors: Mouhab Ayas, Jennifer Le-Rademacher, H. Joachim Deeg, Robert Peter Gale, Stella M. Davies, Rajinder PS Bajwa, Minoo Battiwalla, Shimon Slavin, Bruce Camitta, Marc B Bierings, Richard E. Harris, Richard Olsson, Baldeep Wirk, Biju George, Carmem Bonfim, Wael Saber
Journal: Blood (2011)
The Elevated Expression of FBP1, a Key-Enzyme of Gluconeogenesis Gene, Is Associated to High Sokal Risk In Chronic Myeloid Leukemia Patients.
Authors: Carolina Terragna, Sandra Durante, Annalisa Astolfi, Francesca Palandri, Fausto Castagnetti, Nicoletta Testoni, Marilina Amabile, Ilaria Iacobucci, Simona Soverini, Giuliana Alimena, Massimo Breccia, Fabrizio Pane, Giuseppe Saglio, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli
Journal: Blood (2010)
Coverage with Tetanus, Diphtheria, and Acellular Pertussis Vaccine and Influenza Vaccine Among Pregnant Women — Minnesota, March 2013–December 2014
Authors: Alexandra Barber, Miriam Halstead Muscoplat, Anna Fedorowicz
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

Pertussis and influenza infections can result in severe disease in infants. The diphtheria, tetanus, acellular pertussis (DTaP) vaccine is recommended for infants beginning at age 2 months, and influenza vaccine is recommended for infants aged ≥6 months. Vaccination of pregnant women induces the production of antibodies that are transferred across the placenta to the fetus and provide passive protection until infants are old enough to receive DTaP and influenza vaccines (1-3). To protect young infants before they are age-eligible for vaccination, the Advisory Committee on Immunization Practices (ACIP) has recommended since 2004 that all women who are or will be pregnant during influenza season receive inactivated influenza vaccine (1), and since 2013 that all pregnant women receive the tetanus, diphtheria, acellular pertussis (Tdap) vaccine (3). Tdap and influenza vaccination coverage was assessed among pregnant women in Minnesota. Vital records data containing maternal demographic characteristics, prenatal care data, and delivery payment methods were matched with vaccination data from the Minnesota Immunization Information Connection (MIIC) to assess vaccination coverage. MIIC stores vaccination records for Minnesota residents. Overall, coverage with Tdap vaccine was 58.2% and with influenza vaccine was 45.9%. Coverage was higher for each vaccine among women who received adequate prenatal care compared with those who received inadequate or intermediate care, based on the initiation of prenatal care and the number of recommended prenatal visits attended. Coverage also varied based on mother's race, country of birth or region, and other demographic characteristics. Further study is needed to better understand the maternal vaccination disparities found in this study and to inform future public health initiatives.
Reduced Volume and Pattern of Platelet Aggregation Imaged Using Epifluorescence Digital Videomicroscopy in a High Shear Rate Blood Flow Chamber Permit the Sensitive and Specific Diagnosis of Von Willebrand Disease.
Authors: Eric F. Grabowski, Ming Cheung, Emily E. Biliouris, Rafail I. Kushak, Elizabeth M. van Cott
Journal: Blood (2009)
Osteocyte-Mediated Parathyroid Hormone (PTH) Signaling Regulates Hematopoietic Stem Cells Under Physiologic and Continuous PTH Exposure
Authors: Benjamin J. Frisch, Alexandra N. Goodman, Rhonda J. Staversky, Olga Bromberg, Xiaolin Tu, Teresita M. Bellido, Laura M. Calvi
Journal: Blood (2015)
Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412)
Authors: Catherine S. Diefenbach, Fangxin Hong, Jonathon B. Cohen, Michael J. Robertson, Richard F. Ambinder, Timothy S. Fenske, Ranjana H Advani, Brad S Kahl, Stephen Ansell
Journal: Blood (2015)
Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC
Authors: Kai Chen, Fei Zhou, Wenxiang Shen, Tao Jiang, Xue Wu, Xiaoling Tong, Yang W. Shao, Songbing Qin, Caicun Zhou
Journal: Journal of Thoracic Oncology (2017)
Life-Threatening Complications Suspected Due to Clinical Pharmacokinetic Interaction Between Cyclosporine A and Triazole Antifungal Agents in Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Recipients.
Authors: Ting Yang, Danhui Fu, Jianda Hu, Xiaoyun Zheng, Xiaofeng Luo, Hongqiang Qiu, Xuemei Wu, Ruling Chen, Zhizhe Chen
Journal: Blood (2009)
A Novel, Efficacious Therapeutic Approach to Patients with Acute Promyelocytic Leukemia (APL) Using Differentiating Agent and Metronomic Chemotherapy (CT).
Authors: Shripad D. Banavali, Lovenish Goyal, Reena Nair, Ghanashyam Biswas, Pratibha Amare-Kadam, Chanda Baisane, Shashikant Mahadik, Sumit Gujral, Narayan Karanth, Brijesh Arora, Roshni Bhagwat, Purna Kurkure, Purvish Parikh
Journal: Blood (2005)
Adenovirus Capsid Hexon Is the Main Target Protein of Adenovirus-Specific CD4+ T-Cells: Fundamentals for Targeting Adenovirus by Adoptive Immunotherapy.
Authors: Olga Arbach, Marco Frentsch, Sebastian Voigt, Barbara Chmielewicz, Marco Kaiser, Heins Ellerbrok, Roland Lauster, Andreas Radbruch, Alexander Scheffold, Wolfram Ebell, Andreas Thiel
Journal: Blood (2005)
Physiologic Erythropoiesis with Enhanced Globin Switching and Endogenous Cytokine Production in a Long-Term Serum-free in Vitro human Bone Marrow Biomimicry
Authors: Maria Rende, Iliana Fauzi, Teresa Mortera-Blanco, Johao Miguel da Costa Medeiros, Athanasios Mantalaris, Nicki Panoskaltsis
Journal: Blood (2012)
Overexpression of Deleted Lymphocytic Leukemia 1 (DLEU1) Inhibits Proliferation of Burkitt Lymphoma (BL).
Authors: Sanghoon Lee, Changhong Yin, Janet Ayello, Carmella van de Ven, Charles Biggar, Henry Kwang, Erin Mulvey, James Pao, Mitchell S. Cairo
Journal: Blood (2012)
The Significance of Invasive Breast Cancer Associated With Ductal Carcinoma In Situ (DCIS) Compared With Cancer Without Associated DCIS
Authors: Steven Sorscher
Journal: JAMA Oncology (2017)

To the Editor Recently, in a large randomized study, Vrieling et al1 demonstrated that invasive cancers associated with ductal carcinoma in situ (DCIS) have a higher recurrence rate compared with invasive cancers not associated with DCIS.
Characteristics and Outcome Among 116 Patients with HIV Associated Lymphoma Included in the French ANRS CO16 Lymphovir Cohort Study.
Authors: Caroline Besson, Sophie Prevot, Houria Chavez, Selma Trabelsi, Michele Genin, Patricia Rince, Marie-Caroline Meyohas, Bruno Marchou, Jean Gabarre, Fabrice Bonnet, Cecile Goujard, Francois Boue, Francois Raffi, Maria Partisani, Nicolas Mounier, Yassine Taoufik, Martine Raphael, Dominique Costagliola
Journal: Blood (2012)
FCRL2 Expression Is Predictive of IgVH Mutation Status and Clinical Progression in Chronic Lymphocytic Leukemia.
Authors: Fu Jun Li, Yufeng Li, Mikail A. Shakhmatov, Elena Kashentseva, Jiongru Wu, Laura Z. Rassenti, Thomas J. Kipps, Nicholas Chiorazzi, Randall S. Davis
Journal: Blood (2007)
Outcome of Patients with Philadelphia Positive Chronic Myeloid Leukemia Post Imatinib Failure: Prognostic Significance of ABL Mutation and Additional Clonal Abnormality.
Authors: Monika Conchon, Patricia B Ferreira, Mafalda MY Novaes, Luciana Nardinelli, Mariana Serpa, Pedro Enrique Dorlhiac-Llacer, Dalton FA Chamone, Cristina A Kumeda, Israel Bendit
Journal: Blood (2009)
Generation of GMP-Grade CMV pp65-Specific CD8+ and CD4+ Donor T Cell Lines for Treatment of CMV Reactivation after Transplantation.
Authors: Maarten L. Zandvliet, J.H. Frederik Falkenburg, Inge Jedema, Roelof Willemze, Henk-Jan Guchelaar, Pauline Meij
Journal: Blood (2006)
The Genotype Consisting of Complex Karyotype and TP53 Gene Mutation Is Specific to Acute Myeloid Leukemia with Multilineage Dysplasia
Authors: Yuichi Ishikawa, Hitoshi Kiyoi, Akane Tsujimura, Yasushi Miyazaki, Masao Tomonaga, Kazutaka Kuriyama, Shuichi Miyawaki, Tomoki Naoe
Journal: Blood (2008)
Abstract 406: Interaction of T Cells From Non-ischemic Heart Failure Patients With the Activated Vascular Endothelium is Dependent on Intercellular Adhesion Molecule-1
Authors: Tania A Nevers, Francisco Velazquez, Ane Salvador, Navin Kapur, Pilar Alcaide
Journal: Circulation Research (2015)

Background: Increasing evidence supports a role for inflammation in the pathogenesis of chronic heart failure (HF). Our previous studies demonstrate that T cell recruitment to the heart contributes to the progression of non-ischemic pressure overload induced HF. However, clinical data describing T cell dependent mechanisms contributing to the etiology of this disorder remains unknown. We hypothesized that non-ischemic HF activates human T cells resulting in increased adhesion to the vascular endothelium and recruitment to the heart through mechanisms involving specific endothelial adhesion molecules. Methods and Results: We used T cells from non-ischemic HF patients and non-HF controls as well as left ventricular (LV) tissue from end stage HF after LV assisted device (LVAD) support. Using FACS analysis we found that systemic T cells are significantly elevated in HF patients compared to controls (p&lt;0.05), including Th1, Th17, and Treg cells. Immunohistochemistry analysis revealed that CD3+ and CD4+ T cells infiltrate the LV of HF subjects which were not observed in control. To evaluate the mechanisms through which T cells interact with the vasculature and potentially infiltrate the heart, we used in vitro real time video microscopy under shear flow conditions and found that T cells from HF patients firmly adhered to TNF[[Unsupported Character - Symbol Font &amp;#61537;]] activated HUVECS. Further analysis indicated that HF T cells adhered to ICAM-1, but not to VCAM-1 in higher numbers than control T cells. The surface expression levels of the integrin ligands for VCAM-1 and ICAM-1 (VLA-4 and LFA-1 respectively) were similar between both groups, however, HF T cells exhibited a highly polarized phenotype on ICAM-1 (p&lt;0.005 vs control), suggesting LFA-1 is in its high affinity conformation in HF T cells. Conclusions: Our findings suggest that T cells are activated in non-ischemic HF and have high affinity for the activated endothelium through mechanisms involving ICAM-1- LFA-1 adhesion. Future studies will evaluate the mechanisms regulating LFA-1 activation in HF T cells and their contribution to cardiac remodeling.
The MYST Domain Histone Acetyltransferase TIP60 Interacts with and Is as a Coactivator of the Myeloid Transcription Factor C/EBPα.
Authors: Deepak Bararia, Arun K. Trivedi, Abdul Peer Zada, Hermann M. Behre, Gerhard Behre, Stefan K. Bohlander
Journal: Blood (2006)
Angioimmunoblastic T-Cell Lymphoma (AITL) Is the Most Prevalent T-Cell Lymphoma Entity in Western Europe
Authors: Marie Parrens, Antoine Martin, Laurence Lamant, Richard Delarue, Corinne Haioun, Olivier Tournilhac, Francoise Berger, Céline Bossard, Brigitte Bouchind'homme, Josette Briere, Danielle Canioni, Frederic Charlotte, Bettina Fabiani, Thierry Jo Molina, Martine Patey, Tony Petrella, Jean-Michel Picquenot, Therese Rousset, Virginie Fataccioli, Georges Delsol, Laurence de Leval, Philippe Gaulard
Journal: Blood (2012)
Randomized, Double-Blind, Dose-Finding Study of Dexamethasone in Preventing Acute Emesis Induced by Anthracyclines, Carboplatin, or Cyclophosphamide:
Journal: Journal of Clinical Oncology (2004)

Purpose Different doses and schedules of dexamethasone, combined with a 5-HT3 antagonist, are used to prevent acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. Therefore, we planned a randomized, double-blind, dose finding study aimed to identify the preferred dose and schedule of dexamethasone. Patients and Methods All consecutive chemotherapy-naive patients enrolled onto study were randomly assigned to receive for the prevention of acute emesis, during the first 24 hours, one of the following dexamethasone regimens, in combination with ondansetron 8 mg intravenously (IV): for arm A, 8 mg IV before chemotherapy plus 4 mg orally every 6 hours for four doses, starting at the same time of the chemotherapy; for arm B, 24 mg IV single dose before chemotherapy; and for arm C, 8 mg IV single dose before chemotherapy. All patients received from day 2 to 5 oral dexamethasone 4 mg bid. Results A total of 587 patients were enrolled, and 585 were assessed according to the intention-to-treat principle (195 patients in each arm). The rate of complete protection from acute vomiting and nausea, respectively, was not significantly different among the three groups (arm A, 84.6% and 66.7%; arm B, 83.6% and 56.9%; arm C, 89.2% and 61.0%), nor was the rate of complete protection from delayed vomiting and nausea, respectively (arm A, 81.0% and 46.7%; arm B, 81.3% and 45.1%; arm C, 79.8% and 46.1%). The incidence of delayed vomiting and nausea was strictly dependent on the presence of acute vomiting and nausea. Adverse events were mild and not significantly different among the three groups. Conclusion Dexamethasone 8 mg single dose IV before chemotherapy, in combination with a 5-HT3 antagonist, should be considered the preferred dose to prevent acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide.
Leukemia-Derived DC for T-Cell Therapy against AML Progenitor Cells
Authors: Helga Schmetzer, Anja Liepert, Christine Grabrucker, Dorothea Fischbacher, Markus Freudenreich, Marion Merle, Roland Reibke, Friedhelm Schuster, Susanne Reuther, Andreas Kremser, Julia Loibl, Christoph Schmid, Tanja Kroell, Arndt Borkhardt, Hans-Jochem Kolb
Journal: Blood (2008)
Elevated Serum IL-10 Levels in Patients with Diffuse Large B Cell Lymphoma: A Mechanism of Aberrant JAK2 Kinase Activation
Authors: Mamta Gupta, Mary Stenson, Jing Jing Han, Matthew J Maurer, Linda Wellik, Steven C. Ziesmer, Ahmet Dogan, Thomas E. Witzig
Journal: Blood (2011)
Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).
Authors: Francis Y. Lee, Mei-Li Wen, Rajeev Bhide, Amy Camuso, Stephen Castenada, Krista Fager, Christine Flefleh, Ivan Inigo, David Kan, Roger Luo, Kelly McGlinchey, Richard Smykla, Robert Wild, Robert Borzilleri, Louis Lombardo
Journal: Blood (2005)
Natural Killer Cells Activated By Oncolytic Reovirus Enhance Cetuximab Mediated Antibody Dependent Cellular Cytotoxicity in an in Vitro and In Vivo Model of Colorectal Cancer
Authors: Xing Zhao, Narendiran Rajasekaran, Cariad Chester, Atsushi Yonezawa, Suparna Dutt, Matt Coffey, Zhixu He, Holbrook E Kohrt
Journal: Blood (2015)
Quantitative Analysis of Wilms’ Tumor Gene 1(WT1) Expression in Acute Lymphoblastic Leukemia (ALL) of Adults Reveals Lower WT1 Levels Than in Acute Myeloid Leukemias (AML) and Varying Expression Levels between Individual Patients among Different ALL Subgroups.
Authors: Jan M. Siehl, Eckhard Thiel, Dieter Hoelzer, Stefan Schwartz, Ulrich Keilholz
Journal: Blood (2005)
JMML Revisited: Role Und Outcome of Hematopoietic Stem Cell Transplantation in Subtypes of Juvenile Myelomonocytic Leukemia (JMML)
Authors: Charlotte M Niemeyer, Brigitte Strahm, Michael Dworzak, Barbara De Moerloose, Henrik Hasle, Jan Stary, Markus Schmugge, Marek Ussowicz, Marry Van Den Heuvel, Marco Zecca, Jonas Abrahamsson, Marc Bierings, Bordon Victoria, Susanne Matthes-Martin, Petr Sedlacek, Thomas Gorr, Alexandra Fischer, Peter Noellke, Christian Flotho, Franco Locatelli
Journal: Blood (2012)
Anti-Myeloma Effects Induced by Myeloma Idiotype Pulsed Dendritic Cells In Vitro.
Authors: Mei Zhang, Xiaoran Yin, Yunya Luo, Xiu Lin, Pengcheng He, Mengchang Wang, Jing Li, Yalin Liu, Guili Guo, Ruibo Cai, Lugui Qiu
Journal: Blood (2005)
Local consolidative therapy may be beneficial in patients with oligometastatic non‐small cell lung cancer
Authors: Mary Kay Barton
Journal: CA A Cancer Journal for Clinicians (2017)

Key Points PFS was found to be significantly increased with the use of local consolidative therapy in patients with oligometastatic NSCLC with stable or responding disease after standard frontline systemic therapy. This study provides evidence that is in keeping with an increasingly common approach in patients with advanced NSCLC. Larger studies and longer follow‐up are needed to confirm an overall survival advantage and improve patient selection.
Reply
Authors: Darshan Doshi, Ori Ben-Yehuda, Machaon Bonafede, Noam Josephy, Dimitri Karmpaliotis, Manish A. Parikh, Jeffrey W. Moses, Gregg W. Stone, Martin B. Leon, Allan Schwartz, Ajay J. Kirtane
Journal: Journal of the American College of Cardiology (2017)